Study S001844

A Multi-centre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in Spain

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05443334
Acronym: PIONEER REAL
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 465
Start: 2022-07-28
Primary completion: 2024-07-04
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1240-4149

Registered primary outcomes

Change in HbA1c [From baseline (week 0) to End of Study visit (V3) (week 34-44)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0019038	PIONEER REAL Spain: A multicentre, prospective, real-world study of oral semaglutide use in adults with type 2 diabetes. Delgado Álvarez E, Diabetes, obesity & metabolism	2025	Nonrandomized study	PMID 40555703 DOI	cites ClinicalTrials.gov:NCT05443334; registry reference DERIVED:40555703